Zai Lab (ZLAB) Competitors $35.66 +0.72 (+2.06%) Closing price 07/9/2025 04:00 PM EasternExtended Trading$34.85 -0.81 (-2.27%) As of 04:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZLAB vs. SMMT, ITCI, GMAB, RDY, QGEN, VTRS, ASND, MRNA, BBIO, and BPMCShould you be buying Zai Lab stock or one of its competitors? The main competitors of Zai Lab include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Moderna (MRNA), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Zai Lab vs. Its Competitors Summit Therapeutics Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Qiagen Viatris Ascendis Pharma A/S Moderna BridgeBio Pharma Blueprint Medicines Summit Therapeutics (NASDAQ:SMMT) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends. Do insiders & institutionals believe in SMMT or ZLAB? 4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 84.9% of Summit Therapeutics shares are held by company insiders. Comparatively, 5.0% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor SMMT or ZLAB? In the previous week, Summit Therapeutics had 2 more articles in the media than Zai Lab. MarketBeat recorded 14 mentions for Summit Therapeutics and 12 mentions for Zai Lab. Summit Therapeutics' average media sentiment score of 0.46 beat Zai Lab's score of 0.44 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zai Lab 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer SMMT or ZLAB? Summit Therapeutics presently has a consensus target price of $34.67, indicating a potential upside of 40.12%. Zai Lab has a consensus target price of $54.28, indicating a potential upside of 52.20%. Given Zai Lab's stronger consensus rating and higher probable upside, analysts plainly believe Zai Lab is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 2 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.79Zai Lab 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more risk & volatility, SMMT or ZLAB? Summit Therapeutics has a beta of -1.01, indicating that its stock price is 201% less volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Is SMMT or ZLAB more profitable? Summit Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -60.26%. Zai Lab's return on equity of -33.35% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -62.87% -51.61% Zai Lab -60.26%-33.35%-23.28% Which has preferable earnings & valuation, SMMT or ZLAB? Summit Therapeutics has higher earnings, but lower revenue than Zai Lab. Summit Therapeutics is trading at a lower price-to-earnings ratio than Zai Lab, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K26,248.08-$221.32M-$0.34-72.76Zai Lab$398.99M9.93-$257.10M-$2.49-14.32 SummarySummit Therapeutics beats Zai Lab on 9 of the 17 factors compared between the two stocks. Get Zai Lab News Delivered to You Automatically Sign up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZLAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZLAB vs. The Competition Export to ExcelMetricZai LabMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.88B$2.90B$5.51B$8.95BDividend YieldN/A2.44%5.25%4.02%P/E Ratio-14.3221.0128.0020.16Price / Sales9.93259.24409.36175.34Price / CashN/A41.8337.0657.97Price / Book4.647.868.145.62Net Income-$257.10M-$54.96M$3.16B$248.50M7 Day Performance-2.11%5.27%3.15%4.49%1 Month Performance-10.85%3.78%3.48%7.03%1 Year Performance109.15%5.85%34.27%21.07% Zai Lab Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZLABZai Lab3.2812 of 5 stars$35.66+2.1%$54.28+52.2%+114.6%$3.88B$398.99M-14.321,869SMMTSummit Therapeutics2.4831 of 5 stars$21.28+3.3%$35.09+64.9%+215.6%$15.30B$700K-62.59110ITCIIntra-Cellular Therapies0.7246 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S4.1595 of 5 stars$20.66+0.8%$37.60+82.0%-15.8%$13.15B$3.12B11.742,682News CoveragePositive NewsAnalyst ForecastRDYDr. Reddy's Laboratories2.8028 of 5 stars$15.03-0.3%$16.95+12.8%-5.1%$12.58B$3.81B22.7727,811QGENQiagen3.8835 of 5 stars$48.07+0.6%$49.40+2.8%+23.3%$10.62B$1.98B120.525,765VTRSViatris2.6695 of 5 stars$8.93-0.9%$10.40+16.5%-14.5%$10.57B$14.74B-2.8232,000ASNDAscendis Pharma A/S3.5035 of 5 stars$172.60+0.2%$220.67+27.8%+28.8%$10.53B$393.54M-27.481,017MRNAModerna4.4625 of 5 stars$27.59+1.6%$46.61+68.9%-71.7%$10.50B$3.24B-3.165,800BBIOBridgeBio Pharma4.6896 of 5 stars$43.18-3.7%$58.85+36.3%+78.9%$8.52B$221.90M-12.23400Analyst UpgradeGap UpHigh Trading VolumeBPMCBlueprint Medicines1.5447 of 5 stars$128.18+0.1%$128.06-0.1%+11.5%$8.27B$508.82M-51.89640Insider Trade Related Companies and Tools Related Companies Summit Therapeutics Alternatives Intra-Cellular Therapies Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Qiagen Alternatives Viatris Alternatives Ascendis Pharma A/S Alternatives Moderna Alternatives BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZLAB) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Zai Lab With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ZLAB Stock Alerts